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Correction for “NF-κB activation by the Toll-IL-1 receptor
domain protein MyD88 adapter-like is regulated by caspase-1,”
by Sinead M. Miggin, Eva Pålsson-McDermott, Aisling Dunne,
Caroline Jefferies, Emmanuel Pinteaux, Kathy Banahan,
Caroline Murphy, Paul Moynagh, Masahiro Yamamoto, Shizuo
Akira, Nancy Rothwell, Douglas Golenbock, Katherine A.
Fitzgerald, and Luke A. J. O’Neill, which appeared in issue
9, February 27, 2007, of Proc Natl Acad Sci USA (110:
3372–3377; first published February 20, 2007; 10.1073/pnas.
0608100104).
The authors note that Fig. 3 appeared incorrectly. Panel B (Top)
depicting the time course of NF-κB activation in wild type and cas-
pase-1 deficient peritonealmacrophages is not the same version as the
authors submitted originally to PNAS. A correct version including
vertical rules to indicate splicing is shown below. Regarding panel C,
during the preparation of the manuscript, we inadvertently repeated
a set of p38 blots corresponding to p-p38 Western blots. The correct
p38 Western blots are shown below. The findings of the paper have
not been affected by the error and the authors apologize to the editors
and readers. The corrected figure and its legend appear below.
www.pnas.org/cgi/doi/10.1073/pnas.1317707110
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Fig. 3. Caspase-1 is required for Mal to signal. (A) (Upper) U373 cells were transfected with a 5x NF-κB reporter gene plasmid. Cells were left untreated or
pretreated with YVAD-Cmk (100 μM) or IL-1 receptor antagonist (1 μg/ml) for 1 h. Thereafter, cells were untreated or incubated with LPS (1 μg/ml) or IL-1 (100
ng/ml) for 6 h. Shown is the mean relative stimulation of luciferase activity ± SD for a representative experiment from three separate experiments. (Lower)
THP-1 cells were left untreated or pretreated with YVAD-Cmk (100 μM) or IETD-Fmk (50 μM) for 1 h followed by treatment with Pam3Cys (1 μg/ml) or IL-1
(1 μg/ml) for 0–120 min. Activation of p38 was analyzed by using an anti-phospho-p38-specific antibody. (B) (Top) Time course of NF-κB activation in wild-type
and caspase-1-deficient peritoneal macrophages stimulated with LPS (10 ng/ml), Malp-2 (10 nM), and R848 (10 μM) as detected by EMSA. (Middle) Supershift
assay was performed by using an anti-p65 antibody for 1 h before analysis by EMSA. Protein:DNA complexes are shown. (Bottom) Wild-type and caspase-1-
deficient murine embryonic fibroblasts were treated with LPS (100 ng/ml), lipid A (100 ng/ml), or Malp-2 (10 nM) as indicated, followed by immunoblot
analysis of the cell lysates with antibodies directed against IκBα or β-actin. (C) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal
macrophages stimulated with LPS (100 ng/ml), Malp-2 (10 nM), and IL-1 (1 μg/ml) analyzed by immunoblotting with phospho-p38-specific antibodies. Total
p38 levels are also shown. (D) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal murine embryonic fibroblasts stimulated with LPS
(100 ng/ml) or Malp-2 analyzed by immunoblotting with phospho-p38-specific antibodies. Total p38 levels are also shown.
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Toll-like receptors (TLRs)-2 and -4 are important proteins in innate
immunity, recognizing microbial products and eliciting host defense
responses. Both use the adapter proteins MyD88 and MyD88 adapter-
like (Mal) to activate signaling pathways. Here we report that Mal but
not MyD88 interacts with caspase-1, the enzyme that processes the
precursors of the proinflammatory cytokines IL-1 and IL-18. The
interaction was found in a yeast two-hybrid screen and was con-
firmed by reciprocal GST pull-downs and coimmunoprecipitation of
endogenous proteins. We were unable to implicate Mal in regulating
caspase-1 activation. However, we found that Mal was cleaved by
caspase-1 and that inhibition of caspase-1 activity blocked TLR2- and
TLR4-mediated NF-B and p38 MAP kinase activation but not IL-1 or
TLR7 signaling, which are Mal independent. These responses, and the
induction of TNF, were also attenuated in caspase-1-deficient cells.
Finally, unlike wild-type Mal, a mutant Mal, which was not cleaved by
caspase-1, was unable to signal and acted as a dominant negative
inhibitor of TLR2 and TLR4 signaling. Our study therefore reveals a
role for caspase-1 in the regulation of TLR2 and TLR4 signaling
pathways via an effect on Mal. This functional interaction reveals an
important aspect of the coordination between TLRs and caspase-1
during the innate response to pathogens.
signaling  Toll-like receptor
Toll-like receptors (TLRs) are important activators of the hostinnate immune response. Ten TLRs have been discovered in
humans, and all are characterized as having extracellular leonine-
rich repeat domains and an intracellular Toll/IL-1 receptor (TIR)
domain (1). Upon ligand activation of the TLRs, cytosolic TIR
domain-containing adapter proteins are recruited (1). Four signal-
ing adaptor proteins have been identified, myeloid differentiation
factor 88 (MyD88), MyD88 adaptor-like (Mal), TIR domain-
containing adaptor inducing IFN- (Trif), and Trif-related adaptor
molecule (TRAM), and although the TLRs have similar signal
transduction pathways, there is specificity with regard to their
adaptor usage (2).MyD88 is recruited by all TLRs except TLR3 (3)
and leads activation of the transcription factor NF-B (2). Mal is
required for signaling by the LPS receptor TLR4 and the bacterial
lipoprotein receptor TLR2 (4), and Mal acts as a bridging adapter
for MyD88 recruitment (1). Trif mediates TLR3 and TLR4 signal-
ing and is involved in the activation of another transcription factor,
IRF3 (5). Finally, TRAMmediates TLR4 signaling exclusively (5),
acting as a bridging adapter to recruit Trif to the TLR4 complex.
Caspase-1 plays a key role in inflammatory responses by cleaving
pro-IL-1, pro-IL-18, and probably pro-IL-33 into their bioactive
forms (6, 7). Caspase-1 occurs in multiprotein complexes called
inflammasomes (8), three of which have been characterized to date
(9). One of these inflammasomes comprises the Nod-like receptor
(NLR) protein Nalp1 in a complex with caspase-1, caspase-5, and
the adapter protein apoptosis-associated speck-like protein (ASC)
(10). The second inflammasome contains two other NLRs, Nalp3
and Nalp2, along with caspase-1, ASC, and Cardinal (10). The
Nalp3-containing inflammasome is activated by bacterial RNA,
certain bacterial toxins and ATP, and uric acid crystals (9, 11, 12).
The third inflammasome contains another NLR termed Ipaf, and
caspase-1 is activated by bacterial flagellin (13, 14). ASC has a
particularly important role in caspase-1 activation because ASC-
deficient macrophages are unable to activate caspase-1 in response
to a number of stimuli (15). In all cases so far, TLR ligands are
required to prime inflammasomes for activation, although the
mechanism is not known.
In an effort to discover proteins that interact withMal, we carried
out a yeast two-hybrid screen and identified caspase-1 as a Mal-
interacting protein. Further, signaling by TLR2 and TLR4, but not
TLR7 or IL-1, is impaired in caspase-1-deficient cells, and cleavage
ofMal by caspase-1 is required forMal to signal.We have therefore
revealed an additional function for caspase-1 in the regulation of
TLR2 and TLR4 signaling and provided an important functional
link between TLRs and NLRs in inflammasomes.
Results
Mal Interacts with Caspase-1. By using a yeast two-hybrid-based
screening assaywith full-lengthMal as a bait and a target splenocyte
cDNA library, we identified a total of 20 Mal-positive unique
interacting clones. The most interesting encoded a portion of
caspase-1 spanning the p20 and p10 subunits, which, in the active
enzyme, comprise the catalytic domain. When tested in a bait/
interactor format, Mal was shown to interact with caspase-1 (Fig.
1A, Upper Left, segment a). The N-terminal domain of Mal did not
interact with caspase-1 (segment b), but the TIR domain clearly
interacted (segment c). MyD88 did not interact with caspase-1
(segment e). Fig. 1B Left confirms the interaction whereby GST-
Mal isolated caspase-1 from lysates prepared from HEK293 cells
transfected with AU1-tagged caspase-1 (lane 2). A GST fusion of
the p20 subunit of caspase-1 isolated Mal from HEK293 cells
transfected with HA-tagged Mal (Fig. 1B Right, lane 2). The p10
subunit also isolated Mal but to a lesser extent (lane 3), indicating
that Mal interacts largely with the p20 subunit. Moreover, AU1-
tagged caspase-1 coimmunoprecipitated with HA-Mal (Fig. 1C
Left, lane 4), and HA-Mal-TIR coimmunoprecipitated with AU1-
tagged caspase-1 (Fig. 1CRight, lane 1).Also, using lysates prepared
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from THP1 cells, we found that endogenous Mal coimmunopre-
cipitated with endogenous caspase-1 (Fig. 1D Upper, lane 2). This
result was not due toMal nonspecifically associating with the beads
(Fig. 1D Upper, lane 1). Treatment of THP-1 cells with LPS for 30
min disrupted the association between endogenous caspase-1 and
Mal (Fig. 1D Upper, lane 3). Also, the endogenous Mal-caspase-1
complex was disrupted by theMal inhibitor peptide, which disrupts
interactions mediated by the TIR domain of Mal (16), but not a
control peptide (Fig. 1DLower, compare lanes 2 and 3), confirming
the importance of the TIR domain of Mal for the interaction with
caspase-1.
Mal Is Not Required for Caspase-1 Activation. We next analyzed the
production of mature IL-1 in Mal-deficient macrophages in
response to TLR ligands. Fig. 2A Left shows that wild-type mac-
rophages produced IL-1 in response to LPS, the TLR2 ligand
Malp-2, and the TLR7/8 ligand R848. None of the ligands induced
IL-1 in MyD88-deficient cells, and the LPS and Malp-2 response
was abolished in TLR4- and TLR2-deficient cells, respectively.
IL-1 production was also significantly impaired in Mal-deficient
macrophages treated with LPS orMalp2, as shown by an ELISA on
cell supernatants (Fig. 2A Left) and upon Western blotting of
pro-IL-1whole-cell lysates (Right), the latter also being the case in
MyD88-deficient cells (data not shown). The inability of LPS and
Malp-2 to induce IL-1 production in Mal-deficient macrophages
is therefore likely to be due to effects on expression rather than
processing. We next tested more directly whetherMal was required
for caspase-1 activation by examining caspase-1 processing. The
processed p10 subunit of caspase-1 could be detected in bone
marrow-derived and peritoneal macrophages (data not shown)
from both wild-type (Fig. 2B, lane 4) and Mal-deficient (Fig. 2B,
lane 8) mice.
TLR2 and TLR4 Signaling Is Impaired in Caspase-1-Deficient Cells.We
next tested whether caspase-1 was required for Mal to signal. As
shown in Fig. 3A, preincubation of cells with the caspase-1 inhibitor
YVAD-Cmk blocked the activation of NF-B by LPS. This block-
age was unlikely a result of IL-1mediating the effect of these stimuli
because pretreatment with the IL-1 receptor antagonist had no
effect. The cells are also unresponsive to IL-18. As also shown in
Fig. 3A, the inhibition did not block the effect of IL-1 on NF-B.
We also examined p38MAP kinase activation. We tested Pam3Cys
here because unlike LPS, it only uses the adapters MyD88 andMal
(4, 16, 17). Pretreatment of THP-1 cells with the caspase-1 inhibitor
blocked the early phase activation of p38 MAP kinase (Fig. 3A
Lower, compare top panel with middle panel), whereas a caspase-8
inhibitor was without effect (Fig. 3A Lower). The caspase-1 inhib-
itor did not affect IL-1-mediated activation of p38 MAP kinase
(Fig. 3A Lower, compare upper and lower panels on the right side
of the figure). Moreover, LPS and Malp-2 stimulated caspase-1-
Fig. 1. Mal interacts with
caspase-1. (A) Yeast two-hybrid anal-
ysis of Mal, Mal variants, and MyD88
with caspase-1. Immunoblots indi-
cate the presence of respective pro-
teins. (B and C) Interaction of GST-
Mal (B Left) or GST-p20 or -p10 (B
Right) with lysates from HEK293 cells
transfected with either caspase-1-
AU1 (B Left) or HA-Mal (B Right) and
blotted with relevant antibodies. For
immunoprecipitations, HEK293 cells
were transfected with plasmids en-
coding Mal-HA or caspase-1-AU1 (C
Left) or encoding TIR-Mal-HA, N-
terminal Mal-HA, or caspase-1-AU1
(CRight). (D)THP-1cellsweretreated
with LPS (top blot) for the indicated
times or the Mal inhibitor peptide
(20M) or a control peptide (20M)
for 1 h (bottom blot). After immuno-
precipitation of the complexes with
an IgG control antibody (top blot,
lane 1) or an anti-caspase-1 antibody
(topblot, lanes2and3,andthirdblot
from the bottom, lanes 1–3), and im-
munoblotting was performed using
an anti-Mal antibody.
Fig. 2. Caspase-1 activation does
not require Mal. (A) Wild-type,
MyD88-, Mal-, TLR4-, and TLR2-
deficient peritoneal macrophages
were treated with LPS (100 ng/ml),
Malp-2 (0.01 nM), or R848 (0.01 nM)
for 16 h followed by ATP (5 mM) for
20 min. IL-1 production was then
assessed by ELISA (Left) and West-
ern blot analysis (Right). (B) Wild-
type and Mal-deficient bone mar-
row-derived macrophages were treated with medium or LPS (100 ng/ml) for 16 h followed by ATP (5 mM for 20 min). Lysates were immunoblotted with a
caspase-1 anti-p10 antibody. Results shown are representative of three separate experiments.
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deficient peritoneal macrophages displayed an impairment in
NF-B activation when compared with the TLR 7/8 ligand R848,
as judged in an EMSA (Fig. 3B, top three panels) or by measuring
IB degradation (Fig. 3B, bottom three blots). Similarly, p38 MAP
kinase activation was impaired in caspase-1-deficient macrophages
and murine embryonic fibroblasts treated with LPS or Malp2 (Fig.
3 C and D) but not IL-1 (Fig. 3C). In addition, TNF- levels were
reduced in caspase-1-deficient macrophages treated with LPS and
Pam3Cys (Table 1), whereas TNF- levels were normal after
stimulation withR848. Complete impairment of TNF- production
was not evident in caspase-1-deficient cells because noncleavedMal
may still retain its structural role as a bridging adaptor between
TLR2/4 andMyD88, thereby facilitating impaired signaling through
MyD88. These data indicate a role for caspase-1 in TLR-2 and
TLR-4 signaling but not in TLR 7/8 or IL-1 signaling, the difference
between these sets of receptors being Mal utilization.
Mal Is Cleaved by Caspase-1.Human andmouseMal have a putative
caspase-1 cleavage (18) site (Fig. 4A). As shown in Fig. 4B Top,
treatment of Mal with active recombinant caspase-1 led to the
appearance of an additional form ofMal, 4 kDa less than the major
form (lane 4), consistent with cleavage of Mal by caspase-1 at the
putative caspase-1 cleavage site, and this effect was blocked by
YVAD-Cmk, a caspase-1 inhibitor (lane 5). Mal was not cleaved by
caspase-8 (lane 6) despite caspase-8 activity being confirmed in vitro
as judged by its ability to cleave the fluorogenic substrateAc-IETD-
AMC (data not shown). In addition, mass spectrometry confirmed
that the 21-kDa fragment generated by caspase-1 cleavage lacked
the portion of Mal C-terminal to D198 and thus established the
identity of the cleaved Mal fragment as detected by Western blot
analysis (data not shown). When the caspase-1 cleavage site in Mal
was mutated, generating Mal-D198A, no cleavage occurred (sec-
ond panel, lane 4) and MyD88 was also not cleaved by caspase-1
(Fig. 4BBottom, lane 4). Examination of endogenousMal in THP-1
cells showed it to be cleaved after 15-min treatment of cells with
either LPS (Fig. 4C Left) or Lipid A (Fig. 4C Right). Mal cleavage
correlated with the appearance of the p10 subunit of caspase-1 in
the cell lysates (Fig. 4C Left Lower), indicative of concomitant
caspase-1 activation. Mal cleavage was blocked by a caspase-1
inhibitor (Fig. 4C Right, lane 3). THP-1 cells display caspase-1
activation in response to LPS alone and thus do not require
costimulationwithATP (19, 20). Inmousemacrophages, treatment
with LPS led to the appearance of an additional form of Mal that
was 2.5 kDa smaller in molecular mass than the major form of Mal
(Fig. 4D Left), consistent with cleavage of murine Mal by caspase-1
at the putative caspase-1 cleavage site, and Mal was unaffected in
LPS-treated caspase-1-deficient macrophages (Fig. 4D Right).
These data therefore demonstrate that Mal is cleaved by caspase-1.
Intact Mal Does Not Activate NF-B.Wenext carried out experiments
on Mal-D198A, which cannot be degraded by caspase-1. Mal-
D198A can still interact with caspase-1 (Fig. 4E, lane 4), but as
shown in Fig. 4B, it is not a substrate. Whereas Mal overexpression
activated NF-B, Mal-D198A was inactive (Fig. 4F). Mal-D198A
acted as a dominant-negative inhibitor toward both LPS and
Pam3Cys stimuli (Fig. 4F) but had no effect on TNF- signaling
(Fig. 4F). Using an IL-8 promoter-dependent reporter gene, we
Fig. 3. Caspase-1 is required for
Mal to signal. (A) (Upper) U373 cells
were transfected with a 5x NF-B
reporter gene plasmid. Cells were
left untreated or pretreated with
YVAD-Cmk (100 M) or IL-1 recep-
tor antagonist (1 g/ml) for 1 h.
Thereafter, cells were untreated or
incubated with LPS (1 g/ml) or IL-1
(100 ng/ml) for 6 h. Shown is the
mean relative stimulation of lucif-
erase activity  SD for a represen-
tative experiment from three sepa-
rate experiments. (Lower) THP-1
cells were left untreated or pre-
treated with YVAD-Cmk (100 M)
or IETD-Fmk (50 M) for 1 h fol-
lowed by treatment with Pam3Cys
(1g/ml) or IL-1 (1g/ml) for 0–120
min. Activation of p38 was ana-
lyzed using an anti-phospho-p38-
specific antibody. (B) (Top) Time
course of NF-B activation in wild-
type and caspase-1-deficient peri-
toneal macrophages stimulated
with LPS (10 ng/ml), Malp-2 (10
nM), and R848 (10M) as detected by EMSA. (Middle) Supershift assay was performed by using an anti-p65 antibody for 1 h before analysis by EMSA. Protein:DNA
complexes are shown. (Bottom) Wild-type and caspase-1-deficient murine embryonic fibroblast were treated with LPS (100 ng/ml), lipid A (100 ng/ml), or Malp-2
(10 nM) as indicated, followed by immunoblot analysis of the cell lysates with antibodies directed against IB or -actin. (C) Time course of p38 activation in
wild-type and caspase-1-deficient peritoneal macrophages stimulated with LPS (100 ng/ml), Malp-2 (10 nM), and IL-1 (1g/ml) analyzed by immunoblotting with
phospho-p38-specific antibodies. Total p38 levels are also shown. (D) Time course of p38 activation in wild-type and caspase-1-deficient peritoneal murine
embryonic fibroblasts stimulated with LPS (100 ng/ml) or Malp-2 analyzed by immunoblotting with phospho-p38-specific antibodies. Total p38 levels are also
shown.
Table 1. TNF- secretion from wild-type and caspase-1
KO macrophages
TNF concentration, pg/ml
Stimulus Wild type Caspase-1 KO
None 110  5 98  32
LPS 3,108  24 2,160  14
Pam3Cys 1,906  7 848  48
R848 1,213  22 1,320  51
Wild-type or caspase-1-deficient peritoneal macrophages (0.5  106/well)
were treated with LPS (10 ng/ml), Pam3Cys (100 ng/ml), or R848 (10 M) for
16 h. Cytokine production was then assessed by ELISA. Results shown are
mean SD. A similar result was obtained in another independent experiment.
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show that Mal-D198A does not induce this promoter and that
induction of the IL-8 promoter by Pam3Cys was blocked by Mal-
D198A (Fig. 4G), whereas Mal-D198A did not affect induction by
IL-1 (Fig. 4G). Moreover, HEK293 cells contain ASC, a compo-
nent of TLR-mediated caspase-1 activity (15) (Fig. 4F), and
caspase-1 is activated by treatment of these cells with LPS (Fig. 4F,
lane 5). The mutant Mal was therefore inactive most likely because
it was not cleaved by caspase-1. Taken together, our data therefore
strongly suggest that cleavage of Mal by caspase-1 is required for
Mal to mediate NF-B activation.
Discussion
Our study provides a clear, specific aspect to Mal that distinguishes
it from the other adapters in TLR signaling (4, 5, 21, 22), in that it
is cleaved by caspase-1.WhereasMalwas not required for caspase-1
activation, caspase-1 appeared to be required for the ability of Mal
to activate NF-B. TLR2 and TLR4 signaling was blocked by a
caspase-1 inhibitor and was attenuated in caspase-1-deficient mac-
rophages and murine embryonic fibroblasts. All responses tested
were affected. Moreover, IL-1 and TLR7 signaling remained
normal in these cells. Because the only known difference for these
signals between TLR2 and TLR4 on the one hand and IL-1RI and
TLR7 on the other is a role for Mal, this result provides circum-
stantial evidence that caspase-1 was targeting Mal for activation.
We then demonstrated thatMal is a substrate for caspase-1 and that
a mutant form of Mal, which cannot be cleaved, was unable to
activate NF-B. Finally, we demonstrated that this mutant form of
Mal could still interact with caspase-1 but when overexpressed
Fig. 4. Mal is a substrate for
caspase-1. (A) ClustalW alignment of
the amino acid sequence of human
(top rows) and mouse (lower rows)
Mal with the TIR domain in bold and
the proposed caspase-1 cleavage site
underlined and in bold. (B) for Mal
cleavage assay, whole-cell lysates
generated from HEK293 cells trans-
fected with a plasmid encoding
Mal-HA (Top), Mal-D198A-HA (Mid-
dle), or MyD88-cMyc (Bottom) were
treated with active recombinant
caspase-1 or caspase-8 (Top) in the
presence/absence of the caspase-1 in-
hibitor, YVAD-Cmk. Gels were blot-
ted as indicated. (C) THP1 cells was
screened for Mal cleavage following
LPS (Left Upper) or Lipid A (
caspase-1 inhibitor; Right Upper)
treatment by immunoblotting with
an anti-Mal antibody. Cell lysates
were also immunoblotted with an
antibody against the p10 subunit of
caspase-1 (Left Lower). (D) Wild-type
and caspase-1 peritoneal macro-
phages were screened for Mal cleav-
age after LPS treatment by immuno-
blottingwithananti-Malantibodyor
an anti--actin antibody as a loading
control. (E) HEK293 cells were trans-
fected with plasmids encoding Mal-
D198A-HA or caspase-1-AU1. Immu-
noprecipitated caspase-1-AU1 was
probed for the presence of Mal by
immunoblotting. (F) HEK293 cells
were transfected with a 5x NF-B re-
porter gene plasmid and cotrans-
fected with plasmids encoding
empty vector (EV), Mal (1, 40, and 80
ng), or Mal-D198A (1, 40, and 80 ng)
(Top Left). HEK293-TLR2 (Top Right),
HEK293-TLR4 (Bottom Left), or HEK
293 cells (Bottom Right) were trans-
fected with Mal-D198A (0, 1, 40, and
80 ng) for 24 h. Cells were left un-
treated or treated with Pam3Cys, LPS,
or TNF- for 6 h. In addition, ASC and
the p10 subunit of caspase-1 were
immunoprecipitated from untreated
(lanes 1–4) or LPS-treated (1 g/ml,
30 min, lane 5) HEK293-TLR4 cells us-
ing an anti-human ASC antibody (lane 2; Genentech) or an anti-p10 antibody (lanes 4 and 5) with an IgG antibody serving as a control (lanes 1 and 3). (G) HEK293 cells
were transfected with an IL-8 reporter gene plasmid and cotransfected with plasmids encoding empty vector (EV), Mal (1, 40, and 80 ng), or Mal-D198A (1, 40, or 80
ng) (Top). HEK293-TLR2 (Middle) or HEK293 R1 cells (Bottom) were transfected with Mal-D198A (0, 1, 40, or 80 ng) for 24 h. Cells were left untreated or treated with
Pam3Cys or IL-1 for 6 h. For all luciferase assays, mean relative stimulation of luciferase activitySD from triplicate determinations for a representative experiment from
three separate experiments is shown.
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acted as a dominant negative inhibitor of TLR2 and TLR4 signal-
ing. We were therefore able to conclude that Mal is a substrate for
caspase-1 and must undergo cleavage to be active. The effect of
caspase-1 onMal is unique among the TIR adapters.We found that
MyD88 was not a substrate, and Trif and Tram are unlikely to be
regulated by caspase-1 because similar to MyD88 they lack a
caspase-1 cleavage site in their primary structures. We have there-
fore revealed a mechanism for Mal activation and a function for
caspase-1 in the regulation of TLR2 and TLR4 signaling.
The first question that arises is how caspase-1 might be activated
during TLR2 and TLR4 activation to allow for Mal processing.
Caspase-1 has been shown to occur in different protein complexes
termed inflammasomes (8), of which three have been described to
date (9). How caspase-1 is activated in these inflammasomes is
poorly understood, but in all cases TLR ligands such as LPS appear
to be required for priming of the inflammasome for subsequent
activation by agents such as ATP (15, 23). There is, however,
disagreement in the literature concerning this priming event and
whether TLR activation alone is sufficient to activate caspase-1. A
recent study has shown that ultrapure LPS alone can activate
caspase-1 in murine macrophages (11) or in certain cell lines such
as THP-1 (8). It is possible that the issue here is magnitude; TLR
stimulation alone will activate caspase-1, but this response requires
amplification by endogenous factors such as uric acid orATP,which
acts via Nalp3 (16). Given that Mal requires cleavage by caspase-1
to be active, it is therefore possible that during infection, bacterial
products will be sensed by TLRs but will also lead to the activation
of caspase-1 in inflammasomes, an effect amplified by the gener-
ation of endogenous ligands. Caspase-1 will then process Mal into
its active form, amplifying signaling by TLR2 and TLR4.
Regarding the TLR adapters, caspase-1 activation by LPS has
been shown to be normal in MyD88-, Trif- (24), and, from our
study, Mal-deficient macrophages. The caspase-1 assay relies on
cells primed with LPS or Pam3Cys and then treated with ATP (15).
The responsemeasured is the appearance of the p10 or p20 subunits
of caspase-1, which are indicative of autoprocessing. We cannot
fully rule out a role forMal in caspase-1 function, however, because
the precise role of caspase-1 processing for its activity is uncertain.
Although caspase-1 activationwas unaffected inMal-deficient cells,
we found that the production of IL-1 and IL-18 was impaired,
identifying these cytokines as being on the MyD88/Mal-dependent
pathway. This effect was due to Mal having a role in the induction
of pro-IL-1.
Our results also provide a previously unsuspected function for
caspase-1 activity. Pro-IL-1, pro-IL-18, and possibly pro-IL-33 are
the only previously described physiological substrates for caspase-1
(6, 18, 25). We can now add Mal to this list. Our findings may
explain the profound phenotype of caspase-1-deficientmice, which,
unlike IL-1 and IL-18 knockout (KO)mice, and as recently shown
in IL-1/IL-18 double KOmice (26), are completely resistant to the
effects of LPS (27–29) and are also highly susceptible to infection
with pathogens such as Escherichia coli (30, 31). Similar to our
study, others have shown defects in LPS responses in caspase-1-
deficient macrophages such as induction of TNF, IL-6, and IL-1
(20, 29, 31). TNF production in response to LPS was not affected
by a neutralizing antibody to IL-18 or in IL-1-deficient mice (32,
33). Our data however provide an explanation because the defect
in TLR4 signaling in caspase-1-deficient mice is likely to be because
Mal is not cleaved.
Similar to our study, two other recent studies have found proteins
that interact with caspase-1. Chae et al. (34) have shown that the
protein Pyrin interacts directly with caspase-1 and interferes with its
activation. Sarkar et al. (20) have shown that Receptor Interacting
Protein-2 (RIP2) interacts with caspase-1 and that this interaction
is somehow required forNF-Bactivation, althoughdirect evidence
for this effect was not provided. Similar to our data, NF-B
activation by LPS was attenuated in caspase-1-deficient macro-
phages and was inhibited by a catalytically inactive form of
caspase-1. This effect was interpreted as being due to impairment
in RIP2 activation. Our results provide an additional explanation
because this response may be due to the lack of Mal cleavage in
caspase-1-deficient cells and somehow RIP2 may also be required
for this process. An important outstanding question concerns the
reason why Mal is cleaved by caspase-1. It is possible that an
inhibitory domain is released from Mal. Alternatively, an active
moiety from Mal is released. These possibilities should be exam-
ined. Ultimately, Mal is fully degraded in a SOCS-1-dependent
manner (35).
In conclusion, our findings demonstrate a role for caspase-1 in
inflammation beyond its ability to process pro-IL-18 or pro-IL-1,
implicating it in the regulation of many proinflammatory genes.
Thus, Mal has a specific property among the TLR adapter proteins
in that it requires cleavage by caspase-1 to elicit the downstream
signal NF-B. These findings therefore reveal an important mech-
anism for the coordinated activation of host defense responses by
TLRs and NLR-containing inflammasomes (9).
Materials and Methods
Biological Reagents and Cell Culture. Thioglycollate was from
REMEL Inc. (Lenexa, KS). Highly purified protein-free LPS
derived from E. coli strain 011:B4 was used in all treatments.
Synthetic Malp-2 was from the EMC Microcollection (Tuebin-
gen, Germany). Pam3Cys, human recombinant caspase-1 and
caspase-8, YVAD-Cmk, IETD-Fmk, Mal inhibitor, and control
peptides were from Calbiochem (San Diego, CA). pcDNA3.1-
caspase-1-AU1 was a gift from Seamus Martin (Trinity College,
Dublin). Antibodies to caspase-1 (A-19) and p10 subunit (M-20)
were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit
anti-Mal antibody was raised against full-length human Mal
(Clone R4; Trinity College, Dublin).
Sources of Macrophages.Mal/TIRAP KO, MyD88 KO, TLR4 KO,
and TLR2 KO mice were constructed as described (4, 36, 37).
MyD88KOmicewere backbred toC57BL/6 for 15 generations, and
Mal/TIRAP KO mice were on a mixed C57BL/6 and 129 back-
ground. Caspase-1 KO and wild-type mice were supplied by W.
Wong (BASF Bioresearch Corporation, Worcester, MA). All mice
were confirmed as being homozygous mutants by PCR genotyping
of DNA. All of the animal protocols used in this study were
approved by the Institutional Animal Care and Use Committee at
the University of Massachusetts Medical School (Worcester, MA)
and in accordance with Animals (Scientific Procedures) Act of
1986, United Kingdom.
Yeast Two-Hybrid Analysis. Full-length Mal, TIR domain of Mal,
N-terminal domain of Mal, and full-length MyD88 were sub-
cloned into pGBKT7 downstream of the Gal4 DNA-binding
domain. pGBKT7:full-length Mal was used as a bait to screen a
cDNA library prepared from human splenocytes expressed in
the yeast strain AH109 essentially as described by the manufac-
turer (Matchmaker Gal4 Two-Hybrid System 3; Clontech, Palo
Alto, CA). The combinations tested on His-Leu-Trp-Ade indi-
cate protein–protein interactions.
Reporter Assays. HEK293, HEK293-TLR-4, HEK293-TLR2, and
U373 cells (2  104 cells per well; 96-well plate) were transfected
with 80 ng per well 5x NF-B luciferase reporter gene plasmid and
cotransfected with the expression vectors pcDNA3:Mal or
pcDNA3:Mal-D198A by using GeneJuice essentially as described
by themanufacturer (Novagen,Madison,WI). In all cases, 40 ng per
well of phRL-TK reporter gene was cotransfected to normalize
data for transfection efficiency. HEK293, HEK293-TLR2, and
HEK293-R1 cells (2  104 cells per well; 96-well plate) were
transfected with the 80 ng per well IL-8 promoter reporter plasmid
(38) and cotransfected with the expression vectors
pcDNA3:Mal-HA or pcDNA3:Mal-D198A-HA by using Gene-
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Juice. In all cases, 40 ng per well of phRL-TK reporter gene was
cotransfected to normalize data for transfection efficiency. After
24 h, reporter gene activity was measured as described (38). Data
are expressed as the mean fold induction  SD relative to control
levels, for a representative experiment from a minimum of three
separate experiments, each performed in triplicate.
Transfection, Coimmunoprecipitation, and GST Pull-Down Assays.
HEK293 cells (2  106 cells/10-cm dish) were transfected by using
GeneJuice (Novagen) with the indicated plasmids where the total
amount of DNA (4 g per dish) was kept constant. Twenty-four h
later, cells were lysed as described (38). The indicated antibodies (5
g) were incubated with the cell lysates for 2 h, followed by the
addition of 40 l of 50% protein-G slurry for 1 h. The immune
complexes were precipitated, washed, eluted by the addition of
sample buffer, followed by SDS/PAGE and immunoblotting by
using the indicated antibodies. For GST pull-down experiments,
lysates prepared from HEK293 cells transfected with pcDNA3-
caspase-1-AU1 or pcDNA3-Mal-HA were used in a GST pull-
down assay whereby cell lysates were incubated for 2 h at 4°C with
recombinant GST fusion protein coupled to glutathione-
Sepharose. Complexes were washed three times in lysis buffer,
separated by SDS/PAGE, and immunoblotted as indicated in the
Fig. 1 legend.
Mal Cleavage Assay. Lysates (600 l per each 10-cm dish) prepared
from HEK293 cells transfected (38) with the expression vectors
pcDNA3-Mal-HA or pcDNA3-Mal-D198A-HA (3g of DNA per
dish) were used as substrates in a Mal cleavage assay, as described
for IL-1 (39) using human recombinant caspase-1 (2 l per point)
or caspase-8. Briefly, HEK293 cells overexpressing Mal, Mal-
D198A, or MyD88 were lysed in 500 l of low-stringency IP buffer
(50mMHepes, pH 7.5, 100mMNaCl, 1 mMEDTA, 10% glycerol,
0.5%Nonidet P-40) for 15 min at 4°C followed by centrifugation at
800  g for 5 min. Supernatants (20 l of lysate per point) were
incubated with 2 l of recombinant caspase-1 (100 units) in assay
buffer (100 mMHepes, 10% sucrose, 10 mMDTT, 0.1% CHAPS,
pH 7.5) for 1.5 h at 30°C. Lysates were subjected to SDS/PAGE and
followed by immunoblot analysis.
EMSAs.Murine peritonealmacrophages derived fromwild-type and
caspase-1-deficient mice were stimulated as indicated in the Fig. 3
legend, and their nuclear extracts were prepared as described.
Nuclear extracts (4–8 g of protein) were incubated for 30 min at
4°C with 10,000 counts per minute of double-stranded [-32P]ATP
NF-B oligonucleotide (5-AGTTGAGGGGACTTTCCCAGG-
C-3). Incubations were done in the presence of 2g of poly(dI:dC)
as a nonspecific competitor and 10 mM TrisHCl (pH 7.5) con-
taining 100 mMNaCl, 1 mMEDTA, 5 mMDTT, 4% glycerol, and
100g/ml nuclease-freeBSA.A supershift antibody specific for p65
(SC-8008X; Santa Cruz Biotechnology) was added to the nuclear
extracts 1 h before hybridization with the oligonucleotide. DNA–
protein complexes were resolved on native (5%) polyacrylamide
gels thatweresubsequentlydriedandvisualizedbyautoradiography.
Cytokine Analysis and Caspase-1 Processing Protocol. Thioglycollate-
elicited peritoneal macrophages (5  105 cells per well; 48-well
plate) were stimulated with the following stimuli: LPS (100 ng/ml),
Malp-2 (0.01 nM), and R848 (0.01 nM). For IL-1 release, peri-
toneal macrophages were then treated with 5 mMATP for 20 min.
The medium was then removed and replaced with 600 l of fresh
medium. After 3 h, these cell supernatants were removed and
analyzed for IL-1 release according to the manufacturer’s recom-
mendations (R & D Systems, Minneapolis, MN). To measure
caspase-1 processing, freshly made ATP (5 mM) in regular media
was added for 20 min, and lysates were blotted for caspase-1 using
the p10 antibody as described (15). A similar protocol was used for
bone marrow-derived macrophages.
Immunoblotting for p38. Cells were stimulated with ligand as de-
scribed, and lysates were subjected to SDS/PAGE followed by
immunoblot analysis with an anti-phospho-(Thr180/Tyr182) p38
MAPKor an antibody for total p38 (NewEnglandBiolabs, Ipswich,
MA).
Data Analyses. Statistical analysis was carried out by using the
unpaired Student t test. P values of 0.05 were considered to
indicate a statistically significant difference.
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